BIO
Over the past few years, the number of RNA technologies in the development pipeline has significantly increased, leading to the need for enhanced manufacturing processes. Continuous manufacturing offers several advantages over traditional batch manufacturing, including reduced costs, accelerated production times, and improved product quality.
In a recent Q&A with BioPharma Reporter, ReciBioPharm’s Head of Process Analytical Technology, Analytics Engineering & Data Science, Edita Botonjic-Sehic explains why process analytic technologies (PAT), automation and real-time data analytics are key enablers of continuous RNA manufacturing.
The RNA therapeutics space is relatively new, presenting both opportunities and challenges for the transition from batch to continuous manufacturing. On the one hand, developers can design and construct continuous manufacturing lines from the ground up, bringing greater flexibility and potentially reducing investment requirements. On the other hand, they must carefully consider how they will ensure their processes are robust, flexible and compliant while withstanding the test of time.
By adopting innovative technologies that enable online, inline or at-line analytics throughout the continuous RNA manufacturing process, developers and manufacturers can minimise risk and labor needs, reduce waste and improve quality.
As the demand for RNA therapies continues to rise, developers and manufacturers must consider adapting their continuous manufacturing approaches by leveraging data analytics, machine learning and artificial intelligence to create real-time monitoring and control models throughout the processing chain.
Read the Q&A to learn how analytics help enable continuous manufacturing.